Key Highlights
- Shares of Accuray Incorporated (NASDAQ:ARAY) were quoted at USD 0.1199, down 19.58%, in premarket trading on November 5, 2026, per the premarket quote.
- The board approved a 1-for-40 reverse split on October 28, 2026, effective at 12:02 a.m. ET on November 9, 2026.
- About 120.2 million outstanding shares will become about 3.0 million, and authorized common shares fall from 400,000,000 to 10,000,000.
- Nasdaq granted an extra 180 days, until February 1, 2027, to regain the USD 1.00 minimum bid price.
Reverse Split Announced on November 4
The catalyst is a corporate action. In a release and Form 8-K dated November 4, 2026, Accuray said its board had approved a 1-for-40 reverse stock split, effective at 12:02 a.m. ET on November 9, 2026, with split-adjusted trading under the existing ARAY symbol. Stockholders had approved a range of 1-for-15 to 1-for-40 at a special meeting on October 6, 2026, and the board chose the top of that range on October 28. About 120.2 million shares will become roughly 3.0 million. The stated aim is to regain compliance with the minimum bid price requirement on the Nasdaq Capital Market. In premarket trading on November 5, 2026, the premarket quote showed a decline of 19.58%.
Listing Status and the TCW Financing
A reverse split exchanges many old shares for one new share, raising the quoted price without changing a holder's percentage ownership, apart from cash paid for fractions. Simple arithmetic on the quoted USD 0.1199 gives about USD 4.80 per share on a split-adjusted basis, which is illustrative only. Accuray, a maker of radiation oncology systems, moved from the Nasdaq Global Select Market to the Nasdaq Capital Market effective August 6, 2026, and was granted until February 1, 2027 to regain bid-price compliance. Stockholders also approved the financing with TCW Asset Management, its primary lender and largest shareholder, announced in July 2026. It includes an exchange of USD 40 million of term Loan Debt for convertible preferred stock, a USD 15 million Equity Investment by TCW, a delayed draw term loan of up to USD 5 million and covenant relief through December 31, 2027.
Risks and What to Watch
Conversion of debt into convertible preferred stock and a new equity investment reduce Leverage but add potential dilution for common holders. Reverse splits often see weakness around the effective date, and a higher quoted price does not by itself improve the business. The company filed its Annual Report on Form 10-K on August 27, 2026, and a notice-of-delisting Form 8-K was filed on February 6, 2026. With the shares trading well under USD 1.00, a small number of trades can move the price, spreads can be wide and quoted moves can reverse. Watch the November 9, 2026 split-adjusted open, the closing bid price over the following ten Business days and the February 1, 2027 compliance deadline.
Where Things Stand
The slide at Accuray Incorporated (NASDAQ:ARAY) most plausibly reflects trading around the 1-for-40 reverse split, which is cosmetic for ownership but often accompanies pressure on a sub-dollar stock, and the dilution potential of the TCW preferred stock. The balance of evidence is mixed: financing and covenant relief remove near-term Balance Sheet strain, while the equity remains small. The next catalyst is the split-adjusted open on November 9, 2026.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...